{"id":168609,"date":"2025-08-13T22:15:43","date_gmt":"2025-08-13T22:15:43","guid":{"rendered":"https:\/\/dailytalks.org\/?p=168609"},"modified":"2025-08-13T22:15:43","modified_gmt":"2025-08-13T22:15:43","slug":"multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-in-china","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=168609","title":{"rendered":"Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China"},"content":{"rendered":"<p>HONG KONG, July 25, 2025 &#8211; (ACN Newswire) &#8211; Essex Bio-Technology Limited (\u201cEssex\u201d or the \u201cGroup\u201d, Stock Code: 1061.HK) is pleased to announce that (Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC.The Approved Product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5ml:150mg&#8230;<br \/><a href=\"https:\/\/en.acnnewswire.com\/press-release\/english\/101327\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HONG KONG, July 25, 2025 &#8211; (ACN Newswire) &#8211; Essex Bio-Technology Limited (\u201cEssex\u201d or the<\/p>\n","protected":false},"author":1,"featured_media":168610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-168609","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74-150x67.jpg",150,67,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/08\/168609-multi-dose-diquafosol-sodium-eye-drops-obtained-approval-from-nmpa-for-commercialisation-i689d0e91d6f74.jpg",220,67,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/168609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=168609"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/168609\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/168610"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=168609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=168609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=168609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}